login
Password reminder
Cardiac Rhythm News
Contact the editor Visit Cardiac Rhythm News Twitter feed Visit Cardiac Rhythm News Facebook page
 

An inside view into the FAST trial


Wednesday, 08 Feb 2012 12:00
Manuel Castella
Manuel Castella


By Manuel Castella


Since time that the FAST trial1 was designed in 2007, up to now, there has not been clear evidence to indicate ablation treatments aside from the control of symptoms.2,3 Nevertheless, catheter ablation has expanded its indications thanks to increasing evidence that it is significantly more effective at maintaining sinus rhythm than drug therapy. The expanded indication of catheter ablation has been reflected in the 2011 ACC/AHA/ESC guidelines.3


Although catheter ablation has become a routine treatment for symptomatic atrial fibrillation, two questions arise. First, what is the efficacy to indicate this therapy in patients with left atrium dilatation or with a previous failed catheter ablation? In the FAST trial, two centres with great experience in catheter ablation showed poor results in this subgroup of patients, with 36% actual freedom of arrhythmia at one year.


Thoracoscopic surgery applies the same principles that are applied to catheter ablation to treat atrial fibrillation. Its main difference is that radiofrequency is applied through a bipolar clamp that produces a linear, transmural lesion at the antrum of the pulmonary veins. This avoids most of the dangerous complications in catheter ablation, such as oesophagus lesions or pulmonary vein stenosis. Other lines can be preformed to resemble the Cox-Maze lesion set, but these are made with monopolar radiofrequency; therefore, the possibility of gaps in the line or lack of transmurality exists as in catheter ablation.


Complications in patients in the surgical branch were high in the FAST trial. Interestingly, most of them were due to the essence of it being a new surgical procedure rather than to the technology applied, and therefore a certain learning curve must be appointed.


The agreement by the principal investigators were to start randomising patients after 10 surgeries and, indeed, our first randomised patient in Barcelona was our 11th case. But learning curves are not only about technique. Our anticoagulation protocol started on the third day after surgery. When a patient developed a haemianopsia due to an occipital ischaemic stroke at postoperative day three, we decided to anticoagulate six hours after surgery, and soon after a patient developed an important haemothorax. Our protocol changed to oral anticoagulation at postop day two and after that, we had no more haemorrhagic or ischaemic episodes in more than 50 patients. We are still in a learning process, like catheter ablation was several years ago, when in 2005 the worldwide survey presented a major complications rate of 5%.4


The second question not yet solved is the long-term efficacy of ablation therapy. A recent report with five-year follow-up by the Haissaguerre group has revealed that arrhythmia-free survival rates reaches 29% after a single catheter ablation procedure, and 63% with a mean of two procedures per patient.5 These are discouraging results for such invasive and expensive therapies. Still, we need to know what will be the long-term results with the more consisting surgery-produced ablation lines.


In our opinion and with the actual scientific evidence in hand, most patients with symptomatic paroxysmal or persistent atrial fibrillation refractory to antiarrhythmic therapy should undergo catheter ablation. But after one catheter ablation failure or with left atrium dilatation over 43mm to 45mm, patients would most probably benefit better by thoracoscopic surgery.


Manuel Castella, Department of Cardiovascular Surgery, Hospital Clinic, University of Barcelona, Spain, was a principal investigator in the FAST trial.


References

1. Boersma et al. Circulation 2011. In press

2. Calkins et al. Europace 2007; 9:335–79

3. Wann et al. Circulation 2011; 123:104–23

4. Cappato et al. Circulation 2005;111:1100–05

5. Weerasooriya et al. J Am Coll Cardiol 2011; 57: 160–66




Add New Comment

Most popular


European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices
Tuesday, 31 May 2016
The Netherlands presidency of the European Council and representatives of the European Parliament have reached a political agreement on two draft regulations for medical devices. The new regulations ... European Union agrees new rules for approving medical devices and in vitro diagnostic medical devices

Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction
Wednesday, 08 Jun 2016
Karl-Heinz Kuck has withdrawn his candidacy for president-elect of the European Society of Cardiology (ESC) and also resigned from board of the European Heart Rhythm Association (EHRA). This follows ... Karl-Heinz Kuck steps down from the ESC and EHRA after fraud conviction

Over 90% survival at one-year for patients using wearable defibrillator
Friday, 10 Jun 2016
The WEARIT-II prospective registry of more than 2,000 US patients has found over 90% survival rate at one-year in patients prescribed with the LifeVest wearable defibrillator (Zoll). Over 90% survival at one-year for patients using wearable defibrillator

Features


The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift
Thursday, 09 Jun 2016
We now live in an unprecedented era of technological advances, which is eclipsing our ability to test new therapies at the pace of these advances and the natural history of most heart rhythm ... The challenge of monitoring innovation in modern electrophysiology beyond randomised controlled trials: Time for a cultural shift

Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study
Wednesday, 01 Jun 2016
Pre-clinical data, presented at the 13th International Dead Sea Symposium on Innovations in Cardiac Arrhythmias and Device Therapy (IDSS; 6–9 March, Tel Aviv, Israel), have shown that it is feasible ... Stent-based technology shows promise in isolating pulmonary veins in pre-clinical study

Profiles


Etienne Aliot
Wednesday, 08 Jun 2016
Etienne Aliot (Nancy, France) has always been fascinated by the work of surgeons. This fascination ... Etienne Aliot

George Van Hare
Wednesday, 04 May 2016
George Van Hare (The Louis Larrick Ward professor of Pediatrics and director, Division of Pediatric ... George Van Hare

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions